Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017

Imagem de Miniatura
Arquivos
art_TROEGER_Mortality_morbidity_and_hospitalisations_due_to_influenza_lower_2019.PDF (2.5 MB)
Citações na Scopus
310
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCI LTD
Autores
TROEGER, Christopher E.
BLACKER, Brigette F.
KHALIL, Ibrahim A.
ZIMSEN, Stephanie R. M.
ALBERTSON, Samuel B.
ABATE, Degu
ABDELA, Jemal
ADHIKARI, Tara Ballav
AGHAYAN, Sargis Aghasi
AGRAWAL, Sutapa
Citação
LANCET RESPIRATORY MEDICINE, v.7, n.1, p.69-89, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Although the burden of influenza is often discussed in the context of historical pandemics and the threat of future pandemics, every year a substantial burden of lower respiratory tract infections (LRTIs) and other respiratory conditions (like chronic obstructive pulmonary disease) are attributable to seasonal influenza. The Global Burden of Disease Study (GBD) 2017 is a systematic scientific effort to quantify the health loss associated with a comprehensive set of diseases and disabilities. In this Article, we focus on LRTIs that can be attributed to influenza. Methods We modelled the LRTI incidence, hospitalisations, and mortality attributable to influenza for every country and selected subnational locations by age and year from 1990 to 2017 as part of GBD 2017. We used a counterfactual approach that first estimated the LRTI incidence, hospitalisations, and mortality and then attributed a fraction of those outcomes to influenza. Findings Influenza LRTI was responsible for an estimated 145 000 (95% uncertainty interval [UI] 99 000-200 000) deaths among all ages in 2017. The influenza LRTI mortality rate was highest among adults older than 70 years (16.4 deaths per 100 000 [95% UI 11.6-21.9]), and the highest rate among all ages was in eastern Europe (5.2 per 100 000 population [95% UI 3.5-7.2]). We estimated that influenza LRTIs accounted for 9 459 000 (95% UI 3 709 000-22 935 000) hospitalisations due to LRTIs and 81 536 000 hospital days (24 330 000-259 851 000). We estimated that 11.5% (95% UI 10.0-12.9) of LRTI episodes were attributable to influenza, corresponding to 54 481 000 (38 465 000-73 864 000) episodes and 8 172 000 severe episodes (5 000 000-13 296 000). Interpretation This comprehensive assessment of the burden of influenza LRTIs shows the substantial annual effect of influenza on global health. Although preparedness planning will be important for potential pandemics, health loss due to seasonal influenza LRTIs should not be overlooked, and vaccine use should be considered. Efforts to improve influenza prevention measures are needed.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/31018
Referências
  1. Bedford T, 2015, NATURE, V523, P217, DOI 10.1038/nature14460
  2. Bedford T, 2014, ELIFE, V3, DOI 10.7554/eLife.01914
  3. Campigotto A, 2015, EXPERT REV ANTI-INFE, V13, P55, DOI 10.1586/14787210.2015.981156
  4. Cawcutt K, 2017, CURR OPIN CRIT CARE, V23, P385, DOI 10.1097/MCC.0000000000000435
  5. Christopoulou I, 2015, EXPERT REV VACCINES, V14, P55, DOI 10.1586/14760584.2015.957191
  6. Cohen SA, 2011, J AM GERIATR SOC, V59, P327, DOI 10.1111/j.1532-5415.2010.03271.x
  7. Fineberg HV, 2014, NEW ENGL J MED, V370, P1335, DOI 10.1056/NEJMra1208802
  8. Fleming DM, 2005, EPIDEMIOL INFECT, V133, P255, DOI 10.1017/S0950268804003231
  9. Foreman KJ, 2012, POPUL HEALTH METR, V10, DOI 10.1186/1478-7954-10-1
  10. Fullman N, 2018, LANCET, V391, P2236, DOI 10.1016/s0140-6736(18)30994-2
  11. Gessner BD, 2013, VACCINE, V31, P3222, DOI 10.1016/j.vaccine.2013.05.017
  12. Iskander J, 2013, EMERG INFECT DIS, V19, P879, DOI 10.3201/eid1906.121478
  13. Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
  14. Katz MA, 2012, J INFECT DIS, V206, pS1, DOI 10.1093/infdis/jis548
  15. Kostova D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066312
  16. Labella AM, 2013, MED CLIN N AM, V97, P621, DOI 10.1016/j.mcna.2013.03.001
  17. Lafond KE, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001977
  18. Lin TY, 2013, CURR OPIN VIROL, V3, P531, DOI 10.1016/j.coviro.2013.07.005
  19. Loens K, 2009, J CLIN MICROBIOL, V47, P21, DOI 10.1128/JCM.02037-08
  20. Malosh RE, 2018, VACCINE, V36, P141, DOI 10.1016/j.vaccine.2017.11.018
  21. Morens DM, 2011, REV MED VIROL, V21, P262, DOI 10.1002/rmv.689
  22. Murray CJL, 2006, LANCET, V368, P2211, DOI 10.1016/S0140-6736(06)69895-4
  23. Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9
  24. Nair H, 2013, LANCET
  25. Neuzil KM, 2017, VACCINE, V35, P5734, DOI 10.1016/j.vaccine.2017.08.088
  26. Oxford JS, 2000, REV MED VIROL, V10, P119, DOI 10.1002/(SICI)1099-1654(200003/04)10:2<119::AID-RMV272>3.0.CO;2-O
  27. Pitman RJ, 2013, VACCINE, V31, P927, DOI 10.1016/j.vaccine.2012.12.010
  28. Polansky LS, 2016, EMERG INFECT DIS, V22, P993, DOI [10.3201/eid2206.151521, 10.3201/eid.2206.151521]
  29. Radin JM, 2012, J INFECT DIS
  30. Ruuskanen O, 2011, LANCET, V377, P1264, DOI 10.1016/S0140-6736(10)61459-6
  31. Shi T, 2015, J GLOB HEALTH, V5, P122, DOI 10.7189/jogh.05.010408
  32. Shrestha S, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0233
  33. Stevens GA, 2016, LANCET, V388, pE19, DOI 10.1016/S0140-6736(16)30388-9
  34. Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15
  35. Tempia S, 2017, EMERG INFECT DIS, V23, P1124, DOI 10.3201/eid2307.161959
  36. Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4
  37. Troeger C, 2017, LANCET INFECT DIS, V17, P1133, DOI 10.1016/S1473-3099(17)30396-1
  38. Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2
  39. Zhang H, 2014, VIRUSES-BASEL, V6, P1974, DOI 10.3390/v6051974

Coleções
Artigos e Materiais de Revistas Científicas - HU
Artigos e Materiais de Revistas Científicas - LIM/51
Artigos e Materiais de Revistas Científicas - ODS/03